Nexvet Biopharma plc 4

4 · Nexvet Biopharma plc · Filed Jul 5, 2017

Form 4

Period: 2017-07-01

Chief Executive Officer

Transactions

Exercise/Conversion
Ordinary Shares
2017-07-01$0.13/sh+25,000$3,125→ 74,167 total
Exercise/Conversion
Ordinary Shares
2017-07-01$0.13/sh+35,643$4,455→ 109,810 total
Exercise/Conversion
Restricted Share Units
2017-07-01−25,000→ 50,000 total
Exercise: $0.13From: 2017-07-01Exp: 2020-07-01→ Ordinary Shares (25,000 underlying)
Exercise/Conversion
Restricted Share Units
2017-07-01−35,643→ 106,929 total
Exercise: $0.13From: 2017-07-01Exp: 2020-07-01→ Ordinary Shares (35,643 underlying)

Holdings

Ordinary Shares
(indirect: By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>)
243,587

Footnotes (3)

[F1]The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
[F2]25,000 of the Restricted Share Units vested and became convertible on 7/1/17 and 25,000 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
[F3]35,643 of the Restricted Share Units vested and became convertible on 7/1/17 and 35,643 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.

Documents

1 file